The clinical potential of temsirolimus in second or later lines of treatment for metastatic renal cell carcinoma
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The clinical potential of temsirolimus in second or later lines of treatment for metastatic renal cell carcinoma
Authors
Keywords
-
Journal
Expert Review of Anticancer Therapy
Volume 13, Issue 9, Pages 1021-1033
Publisher
Informa UK Limited
Online
2013-09-12
DOI
10.1586/14737140.2013.833684
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial
- (2013) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2012) B. Escudier et al. ANNALS OF ONCOLOGY
- Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma
- (2012) L. Albiges et al. ANNALS OF ONCOLOGY
- Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis
- (2012) S Bracarda et al. BRITISH JOURNAL OF CANCER
- Second-Line Treatment Outcomes After First-Line Sunitinib Therapy in Metastatic Renal Cell Carcinoma
- (2012) Chi-Chang Chen et al. Clinical Genitourinary Cancer
- Efficacy and Safety of Everolimus in Elderly Patients With Metastatic Renal Cell Carcinoma: An Exploratory Analysis of the Outcomes of Elderly Patients in the RECORD-1 Trial
- (2012) Camillo Porta et al. EUROPEAN UROLOGY
- Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma
- (2012) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- A Pooled Analysis of Sequential Therapies with Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma
- (2012) Frank Stenner et al. ONCOLOGY
- Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma
- (2011) Wolfgang Lamm et al. ACTA ONCOLOGICA
- An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy
- (2011) Viktor Grünwald et al. EUROPEAN JOURNAL OF CANCER
- Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study
- (2011) E. Calvo et al. EUROPEAN JOURNAL OF CANCER
- Sequence Therapy in Patients with Metastatic Renal Cell Carcinoma: Comparison of Common Targeted Treatment Options Following Failure of Receptor Tyrosine Kinase Inhibitors
- (2011) Jonas Busch et al. EUROPEAN UROLOGY
- Sequencing of Agents for Metastatic Renal Cell Carcinoma: Can We Customize Therapy?
- (2011) Guru Sonpavde et al. EUROPEAN UROLOGY
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement
- (2011) C. Porta et al. MEDICAL ONCOLOGY
- Efficacy of Temsirolimus after Previous Treatment with Sunitinib, Sorafenib or Everolimus in Advanced Renal Cell Cancer
- (2011) Michael Grundbichler et al. ONCOLOGY
- Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors
- (2011) Steffen Weikert et al. WORLD JOURNAL OF UROLOGY
- Von Hippel-Lindau (VHL) Inactivation in Sporadic Clear Cell Renal Cancer: Associations with Germline VHL Polymorphisms and Etiologic Risk Factors
- (2011) Lee E. Moore et al. PLoS Genetics
- Temsirolimus in VEGF-refractory metastatic renal cell carcinoma
- (2010) M. J. MacKenzie et al. ANNALS OF ONCOLOGY
- Phase 3 trial of everolimus for metastatic renal cell carcinoma
- (2010) Robert J. Motzer et al. CANCER
- Sequential use of targeted agents in the treatment of renal cell carcinoma
- (2010) Thomas E. Hutson et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- mTOR pathway inhibition in renal cell carcinoma
- (2010) Alvaro Pinto Marín et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma
- (2009) Anil Kapoor et al. CANCER
- Phase I Study Combining Treatment with Temsirolimus and Sunitinib Malate in Patients with Advanced Renal Cell Carcinoma
- (2009) Premal H. Patel et al. Clinical Genitourinary Cancer
- EORTC-GU group expert opinion on metastatic renal cell cancer
- (2009) Theo M. de Reijke et al. EUROPEAN JOURNAL OF CANCER
- Intravenous Temsirolimus in Cancer Patients: Clinical Pharmacology and Dosing Considerations
- (2009) Joseph P. Boni et al. SEMINARS IN ONCOLOGY
- Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review
- (2008) Kiran Gupta et al. CANCER TREATMENT REVIEWS
- Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors
- (2008) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
- (2008) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started